Bone Density Test for Women: What to Know and When
Dr Alex Trevatt27 September 2026Updated 29 September 2026
A bone density test can help answer an important clinical question, but age or menopause alone does not tell a woman that she needs a scan. In the UK, the usual starting point is a review of fracture risk. A clinician then considers DEXA when the result could change treatment, investigation or follow-up.
That distinction matters because a DEXA result is not a direct measurement of bone strength and cannot predict an individual’s future with certainty. It measures bone mineral density. Previous fractures, family history, medicines, health conditions, falls risk and other factors help determine what the number means.
This guide explains when diagnostic bone-density DEXA may be useful, how results are interpreted and why a whole-body body-composition scan answers a different question.
Table of Contents
- Why Bone Density Comes Up in Midlife
- What a Bone Density Test Actually Measures
- How Menopause Changes the Equation for Women
- When the NHS Recommends a DEXA Scan
- Reading a Bone Density Result Without Panic
- Body Composition DEXA Versus Medical DEXA
- Prevention, Repeat Testing and Long-Term Tracking
- Putting It Together with Your GP
Why Bone Density Comes Up in Midlife
Bone is living tissue. Its mineral content and structure change across life in response to age, hormones, nutrition, activity, medicines and disease. Bone loss can occur without pain, so osteoporosis may not become apparent until a fragility fracture occurs.
A fragility fracture is generally a fracture caused by low-energy trauma, such as a fall from standing height or less. A wrist that merely remains sore after a stumble is not evidence of a fragility fracture. Persistent pain after an injury still deserves appropriate assessment, but a fracture needs clinical diagnosis rather than assumption.
Women may begin thinking about bone health in midlife because of menopause, a previous fracture, long-term steroid treatment or a parent’s hip fracture. These are reasons to discuss risk, not automatic instructions to book a scan. The useful question is whether diagnostic DEXA would add information that changes care.
Why a Family Story Can Matter
A parental hip fracture is one recognised factor in fracture-risk assessment. It does not determine a daughter’s outcome, and family history is considered alongside age, previous fracture, smoking, alcohol intake, body size, medicines and relevant health conditions.
The protected British Journal of Radiology study compared hip bone mineral density in several British population cohorts with US reference data. It was published in 2002 and found variation between British cohorts as well as a lower age-adjusted prevalence of low bone density than the US comparison. It should not be turned into a current estimate for all British women or used to decide that an individual needs treatment.
Clinical decisions are more personal. A woman with a previous low-trauma fracture and long-term glucocorticoid exposure has a different risk profile from a woman of the same age with neither factor. Family history can help start the assessment, but no single item completes it.
What a Bone Density Test Actually Measures
DEXA, also written DXA, uses two low-dose X-ray energies to estimate areal bone mineral density, usually expressed in grams per square centimetre. A diagnostic examination commonly measures the lumbar spine and hip because validated reference data and treatment pathways use those sites.
DEXA does not directly measure bone strength, bone quality or fracture probability. Bone mineral density is associated with fracture risk, but bone structure, age, previous fractures, falls and clinical risk factors also matter. Degenerative change in the spine can sometimes make lumbar readings appear higher, which is one reason a clinician or appropriately trained reporter must interpret the examination.
The NHS DEXA overview explains that the result is considered with other information about fracture risk. The scanner provides a reproducible measurement when acquisition and quality control are appropriate. It does not produce a stand-alone verdict.
How DEXA Differs from Other Scans
Quantitative CT can estimate volumetric bone density in three dimensions, but it involves a different method and generally more radiation than DEXA. It is not the routine first-line bone-density examination in the standard UK pathway.
Heel ultrasound uses no ionising radiation and may provide information related to bone, but it cannot substitute for a diagnostic hip-and-spine DEXA when validated central bone mineral density is needed. Ordinary X-rays can identify fractures and some other bone abnormalities, yet they are not a sensitive replacement for measuring bone mineral density.
The appropriate test therefore depends on the clinical question. Back pain with possible vertebral fracture, for example, may require imaging that looks for a fracture rather than a body-composition examination.
The Same Machine Family Can Create Confusion
DEXA technology can also be used for whole-body body-composition analysis. That examination estimates fat mass, lean soft tissue and bone mineral content across the body. Lean soft tissue is not a direct measurement of skeletal muscle, and whole-body bone mineral content is not the validated hip or spine assessment used to diagnose osteoporosis.
Similar hardware does not make the protocols interchangeable. Positioning, acquisition, analysis software, reference populations, quality assurance and reporting purpose can all differ.
The protected legacy Demo DEXA Scan route redirects to a current Telomyx page. The word “DEXA” in a service name still does not establish that it is a diagnostic osteoporosis examination. Before any scan, the person should understand which sites are measured, what the report can answer and who will interpret it.
How Menopause Changes the Equation for Women
Oestrogen helps regulate bone remodelling. During and after the menopause transition, lower oestrogen levels can accelerate bone loss, particularly during the first few years after menopause. The NHS explanation of why DEXA is used describes this relationship and the risk factors that may lead to assessment.
Menopause is not itself a diagnosis of osteoporosis, and it does not mean that every woman needs DEXA. Early menopause, particularly before age 45 without hormone replacement therapy, is one factor that can affect the decision. A previous fragility fracture, low body mass index, smoking, heavy alcohol use, long-term oral glucocorticoids and certain health conditions may also matter.
Bone loss has no reliable day-to-day symptom. This makes structured risk assessment more useful than waiting for a sensation that supposedly reveals low density. It also prevents unverified population percentages or fixed annual bone-loss figures from being mistaken for an individual prediction.
Bone Health Sits Alongside Wider Menopause Care
Bone health is one part of menopause care, alongside symptoms, sleep, mood, sexual health, cardiovascular risk, movement and personal treatment preferences. The protected XO menopause article is a commercial overview rather than NHS guidance. Current clinical decisions should instead follow individual assessment and authoritative guidance such as NICE menopause recommendations.
Hormone replacement therapy should not be started or stopped solely because of one DEXA number. Benefits and risks depend on symptoms, age, time since menopause, medical history and the treatment being considered.
A VO2 max test answers a separate question. It measures aerobic capacity during a graded exercise test and cannot diagnose osteoporosis or replace fracture-risk assessment.
When the NHS Recommends a DEXA Scan
The UK approach is targeted case-finding rather than routine scanning of every woman at a particular birthday. A clinician reviews risk factors and may use a validated fracture-risk tool. DEXA is then considered when bone mineral density is likely to clarify risk or change a management decision.
The NHS DEXA guidance gives examples of people who may be referred, including those over 50 with a risk of osteoporosis and some younger people with relevant risk factors. Age alone is not the whole pathway. In some older or frail people with a clear fragility fracture, treatment decisions may be possible without a scan.
Population screening is a different question from assessing a patient who has clinical risk factors. The UK National Screening Committee currently does not recommend osteoporosis screening for postmenopausal women. In July 2026 it opened a consultation after an evidence review found insufficient evidence to recommend either population or targeted screening programmes (UK NSC consultation announcement). This does not remove the need for clinical case-finding when an individual has recognised risk factors.
Risk Factors That May Prompt Assessment
Factors that may prompt a clinical fracture-risk assessment include:
- a previous fragility fracture;
- a parent who sustained a hip fracture;
- oral or systemic glucocorticoid treatment for three months or longer;
- early untreated menopause or removal of both ovaries before age 45;
- low body mass index;
- current smoking or higher alcohol intake;
- rheumatoid arthritis, coeliac disease, some endocrine disorders or another secondary cause of osteoporosis;
- prolonged absence of periods, malnutrition or an eating disorder;
- height loss, spinal curvature or symptoms that could indicate a vertebral fracture;
- recurrent falls or frailty.
This is not a self-referral checklist and it is not exhaustive. The NHS osteoporosis overview explains common risk factors, while the National Osteoporosis Guideline Group case-finding guidance sets out the role of FRAX, clinical judgement and bone mineral density.
Reading a Bone Density Result Without Panic
A diagnostic report may include a T-score and a Z-score:
- T-score: compares bone mineral density with the reference mean for a healthy young adult of the same sex.
- Z-score: compares it with an age- and sex-matched reference population.
For postmenopausal women, a T-score at an appropriate diagnostic site is commonly described as normal at -1 or above, low bone mass between -1 and -2.5, and in the osteoporosis range at -2.5 or below. The exact value must still be interpreted with site, image quality, clinical history and fracture probability. “Osteopenia” is often used for low bone mass, but it is not a treatment decision by itself.
Z-scores are particularly relevant in younger adults and before menopause. A low Z-score can prompt consideration of secondary causes, but it does not independently diagnose osteoporosis. The protected Telomyx guide to bone-density Z-scores explains the comparison, while the Royal Osteoporosis Society DEXA guide provides patient-focused clinical context.
Small apparent changes between scans are not automatically real biological changes. Scanner precision, positioning and the facility’s least significant change all matter. Comparing measurements from different machines can add further uncertainty.
Why FRAX Still Matters After the Scan
FRAX estimates the 10-year probability of hip fracture and major osteoporotic fracture. It combines clinical risk factors and can incorporate femoral-neck bone mineral density. It is a risk-estimation tool, not a diagnosis and not a substitute for clinical judgement.
Two women with the same T-score can have different fracture probabilities because age, previous fractures, glucocorticoids, smoking, alcohol, rheumatoid arthritis and parental hip fracture affect the estimate. FRAX also has limitations. Some risks are entered only as yes-or-no items, exposure dose is not fully represented, and not every clinically relevant factor is included.
This is why a number near a classification threshold should not be interpreted in isolation. A clinician considers the scan, FRAX or another appropriate tool, previous fractures, possible secondary causes, falls risk and the woman’s priorities together.
Body Composition DEXA Versus Medical DEXA
A diagnostic bone-density examination and a whole-body body-composition examination may use equipment from the same technology family, but they have different purposes.
| Examination | Main output | Appropriate use | Important limit |
|---|---|---|---|
| Diagnostic hip-and-spine DEXA | Site-specific bone mineral density, T-score and sometimes Z-score | Contributes to osteoporosis and fracture-risk assessment when clinically indicated | Does not directly measure bone strength or predict an individual’s fracture with certainty |
| Whole-body body-composition DEXA | Fat mass, lean soft tissue and bone mineral content | Estimates body-composition compartments under an appropriately justified medical pathway | Does not diagnose osteoporosis and does not directly measure skeletal muscle |
The protected legacy Whole Body Composition DEXA Scan route redirects to the current Telomyx service page. Its whole-body purpose must not be confused with diagnostic hip-and-spine bone-density assessment.
Different Questions Require Different Protocols
A diagnostic pathway needs a relevant clinical history, correct acquisition at validated sites, appropriate quality assurance and interpretation that can inform care. A whole-body examination uses different regions and analysis to estimate body-composition compartments.
The March 2026 UK government position on DEXA is explicit that DEXA uses ionising radiation and must be a justified medical exposure. It states that non-medical DEXA for sport or wellness is not justified and is prohibited under the current framework.
An initial interest in body composition, weight management, fitness or sports performance can prompt an enquiry. It cannot itself justify exposure. Product wording, a purchased package or an elapsed interval since a previous scan cannot replace the medical process.
What Mobile Access Can and Cannot Provide
Telomyx provides mobile whole-body DEXA body-composition services in the North West, but access is not automatic. Every Telomyx DEXA request uses a medical questionnaire, requires a referral and is individually justified by an entitled practitioner. A person who is unsuitable or whose exposure cannot be justified is not referred or scanned.
The report can estimate fat mass, lean soft tissue and bone mineral content. It cannot diagnose osteoporosis, replace a medically indicated hip-and-spine DEXA or turn a whole-body number into a treatment recommendation. A person concerned about fragility fractures, unexplained height loss or osteoporosis should speak to a GP or another appropriately qualified clinician.
The protected Telomyx article on DEXA accuracy explains repeat-measurement limitations, while the UK bone-density scan guide distinguishes the questions different scan protocols answer.
Prevention, Repeat Testing and Long-Term Tracking
Bone health is broader than a scan. Weight-bearing activity and progressive resistance exercise can support bone and muscle function, while balance work and a falls assessment may reduce avoidable injury risk. The right plan depends on current health, previous fractures and physical capacity. Sudden high-impact exercise may be inappropriate for someone with vertebral fractures or very high fracture risk.
Nutrition should be considered in context. NHS guidance states that adults need 700 mg of calcium per day, generally obtainable through a varied diet (NHS calcium guidance). It advises adults to consider 10 micrograms of vitamin D daily during autumn and winter, with year-round supplementation for some groups at higher risk of deficiency (NHS vitamin D guidance). Higher doses are not automatically better and can be harmful.
Smoking cessation, alcohol moderation, sufficient food intake and management of underlying conditions can also form part of care. None of these measures means a woman should ignore a fragility fracture or substitute lifestyle advice for indicated medical treatment.
Repeat Scans Should Answer a Clinical Question
There is no universal schedule of one, two, three or ten years that applies to every woman. Repeat DEXA is useful when a new result could change management and when enough time has passed for a meaningful change to be distinguished from measurement variability.
The protected Nottinghamshire osteoporosis guideline is a local primary-care pathway, not a national timetable. Its March 2026 version says that most people have little reason to repeat DEXA until at least five years after starting treatment. It also describes earlier or later clinical reviews in particular circumstances. These intervals must not be extracted into a generic schedule for the public.
NOGG recommends reassessing fracture risk after a new fracture and at clinically relevant treatment-review points. When serial bone mineral density is used, the same facility and machine are preferable where possible, and the change should be judged against that service’s precision error and least significant change.
For Telomyx body-composition DEXA, elapsed time never guarantees a repeat scan. Every request, including a repeat, goes through a fresh medical questionnaire, referral and individual justification. Unsuitable people are not scanned.
Putting It Together with Your GP
A focused appointment begins with the question that needs answering. Useful information can include:
- the date and circumstances of any confirmed fracture;
- family history, especially a parent’s hip fracture;
- menstrual history, including early menopause or prolonged absence of periods;
- current and previous glucocorticoid use;
- smoking, alcohol, falls, height loss and nutrition concerns;
- medical conditions and medicines that can affect bone;
- previous scan reports, ideally including the machine and measured sites.
Questions worth asking include:
- What factors are driving my fracture risk?
- Would a DEXA result change investigation or treatment now?
- Is a diagnostic hip-and-spine examination the relevant test?
- Could a secondary cause of low bone density need investigation?
- If monitoring is proposed, what change would be considered meaningful?
Readers may encounter specialist medicines online. The protected Peptoro abaloparatide page is a commercial peptide directory, not UK prescribing guidance. NICE technology appraisal TA991 recommends abaloparatide only for specified postmenopausal women with osteoporosis who have a very high fracture risk. It is a prescription treatment requiring specialist assessment, not a peptide for self-treatment.
A bone density test is most valuable when the right examination answers a defined clinical question. Risk assessment comes first, the result is interpreted in context, and repeat testing is chosen only when it can alter care.
Telomyx provides mobile DEXA body-composition, VO2 max and resting metabolic rate services in the North West. Current locations and availability are listed on the Telomyx website. Every DEXA request follows the medical questionnaire, referral and individual practitioner-justification pathway described above, with refusal when unsuitable. Medical bone-health concerns require the appropriate clinical assessment and, when indicated, diagnostic bone-density imaging.
The content in this article is for educational purposes only and does not constitute medical or dietary advice. If you have an underlying health condition, are taking medication, or are considering significant changes to your diet or exercise regimen, consult a qualified healthcare professional before making any adjustments.
